Abbott Raises Stake in Ibis Biosciences by $20M; Retains Right to Buy

Jul 01, 2008

NEW YORK (GenomeWeb News) – Abbott has invested a second $20 million in pathogen detection developer Ibis Biosciences, upping its stake in the company to 18.6 percent, Ibis parent firm Isis Pharmaceuticals said today.

The agreement follows a $20 million investment that Abbott made in January that gave it a 10.25 percent stake in the firm.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

Mysterious Third Group

An artificial intelligence-based analysis suggests a third group of ancient hominins likely interbred with human ancestors, according to Popular Mechanics.

This Week in Science

In Science this week: reduction in bee phylogenetic diversity, and more.

In the Past

The New York Times Magazine looks into paleogenomics and how it is revising what's know about human history, but also possibly ignoring lessons learned by archaeologists.

New Bases, New Drugs

The Economist reports on Synthorx's efforts to use expanded DNA bases they generated to develop a new cancer drug.

Main menu